Clinical significance of preoperative imatinib therapy in stomach gastrointestinal stromal tumors
10.11904/j.issn.1002-3070.2015.05.009
- VernacularTitle:胃间质瘤术前辅助伊马替尼治疗的临床意义
- Author:
Wenye PEI
;
Jun ZHANG
;
Fujun YAN
;
Ping WANG
;
Yan ZHAO
- Publication Type:Journal Article
- Keywords:
Gastrointestinal stromal tumor(GIST);
Imatinib;
Preoperative treatment;
Multidisciplinary team( MDT)
- From:
Practical Oncology Journal
2015;29(5):424-427
- CountryChina
- Language:Chinese
-
Abstract:
Objective Gastrointestinal stromal tumor( GIST) is a rare mesenchymal tumor from gastroin-testinal tract,and surgery remains the only curative treatment.In order to improve the outcome of surgical treat-ment,reduce the risk of surgery,and increase the quality of life,preoperative imatinib( IM) treatment for GIST is investigated.Methods We retrospectively studied the multidisciplinary team model treatments for 8 GIST cases receiving preoperative IM treatment.The cases were prescribed IM of 400 mg daily for 12 to 40 weeks and exten-sively followed until surgery was considered feasibleg.The clinical significance and safety profile were analyzed. Results Partial responsive rate was 62.5% in this study.There was no intolerable sever adverse effects by IM preoperative treatment.All the cases received R0 dissection,with no intraoperative tumor rupture.The postopera-tive recovery was satisfied.Conclusion IM preoperative treatment brings significant clinical benefit to large stomach GISTs and cardiac region GISTs.The preoperative treatment should be monitored carefully under a multi-disciplinary team.Preoperative IM treatment is an evocative treatment strategy for high risk GIST.
